Article
Dermatologists who administer chemotherapy and other drugs in their offices could see significant reductions in reimbursement levels as a result of an effort by the federal government to curtail Medicare's costs for drugs used to treat cancer.
How OJM Group Can Help Dermatologists Reach Their Financial Goals in 2025 and Beyond
The Cutaneous Connection: Episode 18-Cybersecurity Within the Dermatology Practice
Wealth Strategies for Today’s Physician: David Mandell, JD, MBA, Shares Insights from New Playbook
POLL: Is Your Practice Closed for the Holidays?
Maximizing the 2-Fold Benefits of Your Charitable Donations
Which Tax Treatment Is Best for Your Dermatology Practice?